About Us
Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
Because together, we are stronger.
Our leadership team
Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities:
RECEPTOR
BIOLOGY
MUSCLE
BIOLOGY
ANTIBODY
ENGINEERING
OLIGONUCLEOTIDE
DESIGN
DRUG DISCOVERY &
DEVELOPMENT
RARE MUSCLE
DISEASES
LINKER
CHEMISTRY
CLINICAL
DEVELOPMENT
LEADERSHIP TEAM
Romesh Subramanian, Ph.D.
President and
Chief Executive Officer
Romesh brings extensive drug discovery, translational medicine and leadership experience to Dyne. He formerly led new modality discovery research at Alexion Pharmaceuticals, focusing on nucleic acid, antibody and enzyme replacement therapies. Previously, he co-founded RaNA Therapeutics, now Translate Bio, a company leveraging long non-coding RNA to increase gene activation for rare disease therapies. Prior to co-founding RaNA, Romesh held positions of increasing responsibility at Pfizer and Thrasos Therapeutics, a biotechnology startup. Currently, he is an entrepreneur-in-residence at Atlas Venture, Founder of Dyne Therapeutics, and also serves on the advisory board of the Harvard Medical School Initiative for RNA Medicine.
Romesh earned his B.S. from Loyola University, his M.S. from Duke University, and his Ph.D. from Emory University.
Jonathan McNeill, M.D.
Vice President, Business Development
Jonathan brings life science business development and corporate strategy experience to Dyne. Most recently, Jonathan held a business development role at Editas Medicine, where he completed a variety of significant transactions, led strategic planning activities, and collaborated on the company’s initial public offering. Prior to Editas, Jonathan was a consultant at the Boston Consulting Group, focusing on the pharmaceutical and biotechnology sectors. He was previously a healthcare services researcher at The University of North Carolina at Chapel Hill.
Jonathan earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania and his Bachelor of Arts in public policy and economics from UNC Chapel Hill, where he was a Morehead-Cain Scholar.
Joanne Bryce
Director, Finance
Joanne brings over 25 years of experience leading the finance and operations organizations of early-stage companies. She previously served as chief financial officer of Quartet Medicine, a biotechnology company that focused on developing novel treatments for chronic pain. She also advises early-stage, venture-backed biotechnology companies Arkuda Therapeutics and Disc Medicine. Prior to her career in the biotechnology industry, Joanne held chief financial officer roles at a number of technology companies, including WiTricity, Speedy Packets and Narrative Communications, where she led the finance role in the sale of Narrative to At Home Corp. Joanne began her career at Arthur Andersen and is a certified public accountant licensed in the Commonwealth of Massachusetts.
Joanne holds a B.S. from Babson College.
Bruce Wentworth, Ph.D.
Senior Scientific Advisor
Bruce has devoted much of his professional life to developing therapies for rare genetic diseases, particularly myopathies. Previously, he was vice president and head of research for Sarepta Therapeutics, leading a team whose work contributed to the FDA approval of Exondys 51, a treatment for Duchenne muscular dystrophy (DMD). Prior to Sarepta, Bruce spent 21 years as a senior research director in the rare disease group at Genzyme (later Sanofi), with a focus on myopathies including DM1, facioscapulohumeral muscular dystrophy, DMD and Pompe disease. Bruce currently serves as an independent consultant guiding Dyne and other companies in the preclinical development of therapeutics for rare diseases, as well as in the design of portfolio-based research organizations.
Bruce received his Ph.D. from the University of Massachusetts Medical School and also studied at Harvard Medical School and Boston University Medical School, where he was a fellow of the American Heart Association.
Mo Qatanani, Ph.D.
Vice President, Discovery
and Translational Research
Mo brings extensive experience in developing and advancing multiple therapeutic modalities for metabolic and rare diseases. He was previously director of discovery research at Alexion Pharmaceuticals, where he led drug discovery research programs and collaborations at the company’s Lexington, MA site. Prior to Alexion, Mo led drug discovery at Synageva BioPharma, developing multiple new programs for rare diseases while building and managing a fully externalized research model. Mo began his drug discovery work at the cardiometabolic disease division at Merck Research Laboratories, leading multiple internal programs and strategic partnerships.
Mo holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed his post-doctoral fellowship at the University of Pennsylvania School of Medicine. He obtained his B.S. and M.S. in biology from the American University of Beirut.
Board of directors
Scientific Advisory Board
INVESTORS
We are supported by a group of leading investors who share our pioneering mission.
